Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.
Thalidomide has been proved to play an important role in rescue treatment of patients with refractory/relapsed multiple myeloma (MM). However, thalidomide therapy is associated with numerous side effects, mainly somnolence, constipation, fatigue or peripheral neuropathy. We report three patients diagnosed with MM and treated with thalidomide as salvage therapy who developed severe renal failure when they received aminoglycoside antibiotics. This observation suggests that thalidomide can potentiate nephrotoxicity of aminoglycoside antibiotics in patients with MM.
Montagut
Clara
C
Department of Hematology, Institute of Hematology and Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain.
Bosch
Francesc
F
Villela
Luís
L
Rosiñol
Laura
L
Bladé
Joan
J
D000368:Aged; D000583:Amikacin / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D051437:Renal Insufficiency / Q000139:chemically induced*; D016879:Salvage Therapy; D013792:Thalidomide / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D013792:Thalidomide; D000583:Amikacin